Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin

Heart failure (HF) is associated with a high morbidity and mortality burden. In light of more recent evidence, SGLT2 inhibitors are currently recommended as first-line therapy in managing patients with HF, regardless of ejection fraction, to reduce HF burden. The DAPA-HF and DELIVER trials, and part...

Descripción completa

Detalles Bibliográficos
Autores principales: Escobar, Carlos, Pascual-Figal, Domingo, Manzano, Luis, Nuñez, Julio, Camafort, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649290/
https://www.ncbi.nlm.nih.gov/pubmed/37959263
http://dx.doi.org/10.3390/jcm12216798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649290/
https://www.ncbi.nlm.nih.gov/pubmed/37959263
http://dx.doi.org/10.3390/jcm12216798

Ejemplares similares